Unity Biotechnology ^{Priced, Nasdaq: UBX}

We are a preclinical biotechnology company engaged in researching and developing therapeutics with a mission to extend human healthspan, the period of one's life unburdened by the diseases of aging. Enabled by foundational scientific insights, we have devoted over six years to identifying multiple mechanisms that we believe to be root causes of age-associated disease. We are utilizing these insights to develop a broad portfolio of drug candidates to treat these diseases of aging. UBX0101 is our lead drug candidate for musculoskeletal disease with an initial focus on osteoarthritis. This drug candidate is a potent senolytic small molecule inhibitor of the MDM2/p53 protein interaction. Disruption of this protein interaction can trigger the elimination of senescent cells. We submitted our investigational new drug, or IND, application in March 2018, and we plan to initiate a Phase 1 clinical study in osteoarthritis in the first half of 2018. UBX1967 is our lead drug candidate for ophthalmologic diseases; we plan to submit our IND application and commence a Phase 1 study in the second half of 2019.